NASDAQ · STOCK
Exelixis
$53.05
52W $33.76 – $57.57
63/100
$13.33B
17.0
0.42
Is EXEL Bullish or Bearish?
Bullish.
Innellis AI committee rates Exelixis (EXEL) Buy with a composite score of 63/100
, based on 7 analysts with 71% agreement.
Last updated August 01, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +12.29 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -7.71 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is price-to-book of 5.4x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull & Bear Case
Bull Case
- ROE of 40.2% shows genuine earnings power backing the valuation — Value
- EPS growing 64.0% YoY — Growth
- 4 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price-to-book of 5.4x prices in significant intangible value — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
- Price trading below the lower Bollinger Band -- stretched to the downside — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 01, 2026
Overall Committee Score
63/100
Agreement
71%
Analysts
7
Conviction
Moderate
Sector Rank
Top 7%
of 93 Healthcare peers
Value Analyst
neutral
59
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 40.2% shows genuine earnings power backing the valuation
− Price-to-book of 5.4x prices in significant intangible value
Growth Analyst
bullish
60
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 64.0% YoY
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst
bullish
80
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
Macro Analyst
bullish
70
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
bullish
64
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.20 across 10 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2535.03)
Investment Thesis Evolution
Committee score moved marginally from 60.3 to 62.7.
- Conviction changed from contested to moderate.
- Committee agreement increased notably from 57% to 71%.
- New bearish signals: 3 appeared.
- Bullish support removed: 1 signal(s) disappeared.
- New bullish signals: 1 appeared.
- Bearish pressure eased: 2 signal(s) disappeared.
- Analyst(s) changed stance: Macro Analyst.
Analyst-level changes:
- Macro Analyst: stance neutral->bullish; score 58->70 (+12).
- News Analyst: +1 bullish signal(s).
- Portfolio Manager: +2 bearish signal(s).
- Risk Analyst: score 75->80 (+5).
- Technical Analyst: +1 bearish signal(s).
Comparing 2026-07-31 to 2026-08-01 (1 day apart).
Technical Analysis
RSI (14)
31.9
Neutral
MACD Histogram
-0.362
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
-0.31
Below Lower Band
Price vs Moving Averages
EMA 9
$55.22
Below
EMA 21
$55.13
Below
EMA 50
$53.34
Below
EMA 200
$46.99
Above
Fundamental Analysis
Valuation
69
Growth
69
Profitability
2
Financial Health
100
Cash Flow
37
Valuation
P/E Ratio
17.0×
P/B Ratio
7.08×
PEG Ratio
0.43
Dividend Yield
0.00%
52W High
$57.57
52W Low
$33.76
Quality & Growth
ROE
36.2%
ROA
27.5%
Gross Margin
96.4%
Operating Margin
39.4%
Revenue Growth YoY
—
Debt / Equity
0.09
AI Fundamental Assessment
P/E ratio of 17.0 (inexpensive relative to a 15-40x range); Price-to-book of 7.1x; PEG ratio of 0.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.4%; Return on assets of 0.3%; Net margin of 0.4%; Gross margin of 1.0%; Current ratio of 3.26 (healthy short-term liquidity); Debt-to-equity of 0.09; Free cash flow margin of 1.0% (thin cash generation); Free cash flow per share is positive (3.55); Most recent quarter beat estimates by 10.1%; 4 consecutive earnings beats; EPS growth decelerating (+27.5% -> -10.2% QoQ); Analyst estimates rising over recent quarters
Get the Full EXEL Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →